NEWS

Stay Up-To-Date On All Things IMAC!

IMAC’s BioFirma Subsidiary Announces Registered Status with U.S. Food and Drug Administration

BRENTWOOD, Tenn. (August 13, 2019) – IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces its BioFirma subsidiary has received “Registered” status with the U.S. Food and Drug Administration (FDA). This registration permits the BioFirma laboratory to package, process, store, label and distribute human cells and tissue.  IMAC is now using BioFirma’s NeoCyte® regenerative medicine products in its rehabilitation clinics. BioFirma is now selling amniotic fluid exosomes to licensed medical doctors in the United States.  BioFirma recorded sales of the first exosome product in the second quarter.  Ian White, Ph.D., the company's chief scientific officer, and president of BioFirma was recently featured in the docuseries 'Pain Revealed' where he highlighted opportunities of regenerative medicine that he has researched in his career. “Twenty...

IMAC HOLDINGS ANNOUNCES FAVORABLE NEW LONG-TERM OUTCOMES DATA FROM REGENERATIVE REHABILITATION FOR MUSCULOSKELETAL CONDITIONS

May 27, 2019 IMAC HOLDINGS ANNOUNCES FAVORABLE NEW LONG-TERM OUTCOMES DATA FROM REGENERATIVE REHABILITATION FOR MUSCULOSKELETAL CONDITIONS At an Average of 17 Months Post-Treatment, Quality-of-Life Score Improved 50% and Pain was Reduced 46% Without the Use of Opioids BRENTWOOD, Tenn. (May 28, 2019) – IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of Innovative Medical Advancements and Care, specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announces new data showing long-term post-treatment outcomes for 130 regenerative-rehabilitation patients treated at IMAC Regeneration Centers. Musculoskeletal conditions treated included 45 knee patients, 42 spine patients and 43 patients with multiple and other conditions (shoulder, hip, elbow, thigh, wrist, thumb, calf and/or ankle). Data collection averaged 17.3 months post-treatment with an average patient age of 61.7 years. Outcomes data was collected...

IMAC Holdings Enters Greater Chicago Market with Acquisition; Will Rebrand as Mike Ditka IMAC Regeneration Centers

All-stock transaction expected to close in Q2 2019 BRENTWOOD, Tenn. (April 2, 2019) – IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of innovative medical advancements and care, specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces the signing of a merger agreement to acquire ISDI Holdings, Inc. (“ISDI”), a practice management group that manages three clinics in the Chicago area. The three managed clinics had consolidated net revenue of $5.0 million and net income of $0.8 million for the 12 months ended December 31, 2018. Under the terms of the merger agreement, IMAC will issue 1,002,306 shares of common stock at closing, which is expected to occur in the second quarter of 2019 following the satisfaction of certain conditions included in the merger agreement. Pursuant to the merger agreement, ISDI Holdings, Inc., the parent company of the Chicago clinics’ management, will merge with and into IMAC’s wholly-owned subsidiary...

IMAC Holdings Reports 2018 Fourth Quarter and Year-end Patient Visits and Procedure Volumes Featuring Double-digit increases

BRENTWOOD, Tenn., March 20, 2019 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of Innovative Medical Advancements and Care, specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces patient visits and procedure volume at its IMAC clinics during the 2018 fourth quarter (Q4) and full year. All figures listed below for all periods are noted as either actual or pro forma. Actual procedure and visit counts are inclusive of actual patient visits and procedures for all clinics owned or managed by IMAC Holdings during the period. Pro Forma procedure and visit counts reflect the completion of our transactions consummated through December 31, 2018 as if they had occurred on January 1, 2017. Fourth Quarter 2018 IMAC Actual: Procedures and Visits IMAC Holdings experienced a 1,420.6% growth in visits during Q4 of 2018 compared to Q4 of 2017. Visit counts jumped from 2,012 in Q4 of 2017 to 30,595 in Q4 of 2018. Procedure...

IMAC Engages Legendary Football Player and Coach Mike Ditka as Brand Ambassador for the Chicago Area

Photo By: premierespeakers.com Target Clinic Identified for Expansion into Chicago Market BRENTWOOD, Tenn, March 14, 2019 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC), a provider of Innovative Medical Advancements and Care, specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, announces that Mike Ditka has been engaged to serve as brand ambassador for the Company’s planned expansion into the Chicago market. Mr. Ditka, a three-time Super Bowl champion and 11-year coach of the Chicago Bears, joins other IMAC iconic brand ambassadors including Tony Delk, Ozzie Smith and David Price to bring awareness to IMAC’s conservative approach to treating mobility impairments. Mr. Ditka, known as “Iron Mike” because of his upbringing in a Pennsylvania steel town, is one of only two people to win an NFL title as a player, an assistant coach and a head coach, and one of only four people to win a championship as head coach of a team he...